These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 5286254)

  • 21. [Relation of visual evoked potentials to the clinical state in patients with chronic renal insufficiency].
    Kuba M; Peregrin J; Vít F; Hanusová I; Zahradník J
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl; 1983; 26(3):217-23. PubMed ID: 6335784
    [No Abstract]   [Full Text] [Related]  

  • 22. [On the renal excretion of Methyprylon (Noludar) and its metabolites in humans].
    Bösche J; Riebel F; Schmidt G
    Arch Toxikol; 1969; 25(1):65-75. PubMed ID: 5806381
    [No Abstract]   [Full Text] [Related]  

  • 23. Resting metabolic rate in chronic renal failure.
    Kuhlmann U; Schwickardi M; Trebst R; Lange H
    J Ren Nutr; 2001 Oct; 11(4):202-6. PubMed ID: 11680000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Urinary excretion of rifampicin in kidney failure when administered alone or together with isoniazid].
    Titarenko OT; Vakhmistrova TI; Perova TL
    Antibiotiki; 1983 Sep; 28(9):698-702. PubMed ID: 6638984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
    Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fractional excretion of magnesium of chronic renal failure patients in Lagos, Nigeria.
    Oladipo OO; Onubi J; Awobusuyi O; Afonja OA
    Niger Postgrad Med J; 2003 Sep; 10(3):131-4. PubMed ID: 14692052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
    Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Excretion of 2, 4-dioxo-3, 3-diethyltetrahydropyridine in humans and effect of various drugs].
    PRIBILLA O; ZILLINGER G
    Arzneimittelforschung; 1956 Nov; 6(11):681-5. PubMed ID: 13395918
    [No Abstract]   [Full Text] [Related]  

  • 29. [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency].
    Hottelart C; el Esper N; Achard JM; Pruna A; Fournier A
    Nephrologie; 1999; 20(1):41-4. PubMed ID: 10081035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residual chloroquine and metabolites in man as a sequel of previous chloroquine medications: a urinary excretion study and its significance.
    Essien EE; Ifudu ND
    J Trop Med Hyg; 1984 Jun; 87(3):131-6. PubMed ID: 6512905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Creatinine clearance calculations in creatininemia are an indispensable parameter for clinicians].
    Halimi JM; Blanchecotte F; Nivet H; Laouad I
    Ann Biol Clin (Paris); 2002; 60(5):511-2. PubMed ID: 12368136
    [No Abstract]   [Full Text] [Related]  

  • 32. [Urinary excretion of amylase in patients with renal insufficiency. Correlation with blood amylase, urine creatinine and proteinuria levels].
    García-Valdecasas Valverde J; González Calvín J; Hervás Sánchez J; Manjón García M; Delgado Lillo R; Cerezo Morales S; Peña Yáñez A
    Rev Esp Enferm Apar Dig; 1984 Jun; 65(6):491-7. PubMed ID: 6206529
    [No Abstract]   [Full Text] [Related]  

  • 33. [A comparative study of the circulation of oxytetracycline and its derivatives--methacycline and doxycycline--in the bodies of animals].
    Iakovlev VP
    Antibiotiki; 1973 Nov; 18(11):1041-6. PubMed ID: 4799125
    [No Abstract]   [Full Text] [Related]  

  • 34. Risk factors of renal failure progression two years prior to dialysis.
    Mazouz H; Kacso I; Ghazali A; El Esper N; Moriniere P; Makdassi R; Hardy P; Westeel PF; Achard JM; Pruna A; Fournier A
    Clin Nephrol; 1999 Jun; 51(6):355-66. PubMed ID: 10404696
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Factors in the progression of renal insufficiency other than dyslipidemia].
    Mazouz H; Kacso I; Oprisiu R; el Esper N; Makdassi R; Pruna A; Fournier A
    Nephrologie; 2000; 21(7):343-4. PubMed ID: 11200606
    [No Abstract]   [Full Text] [Related]  

  • 36. [Differences between the glomerular filtration rate estimated by the MDRD equation and the measurement of creatinine and urea clearance in unselected patients with terminal renal insufficiency].
    Caravaca F; Arrobas M; Luna E; Naranjo M; Pizarro JL; Sánchez-Casado E
    Nefrologia; 2002; 22(5):432-7. PubMed ID: 12497744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Busulfan clearance in renal failure and hemodialysis.
    Ullery LL; Gibbs JP; Ames GW; Senecal FM; Slattery JT
    Bone Marrow Transplant; 2000 Jan; 25(2):201-3. PubMed ID: 10673681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Possible mechanisms of polyuria in progressive chronic renal failure].
    Natochin IuV; Bogolepova AE
    Ter Arkh; 2000; 72(6):15-20. PubMed ID: 10900642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calculation of creatinine clearance from plasma creatinine.
    McLigeyo SO
    East Afr Med J; 1993 Jan; 70(1):3-5. PubMed ID: 8513724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma and urinary catecholamines and their metabolites in chronic renal failure.
    Darwish R; Elias AN; Vaziri ND; Pahl M; Powers D; Stokes JD
    Arch Intern Med; 1984 Jan; 144(1):69-71. PubMed ID: 6691776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.